Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab + evorpacept + dexamethasone in relapsed or refractory multiple myeloma
2024-514993-38-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2 trial of isatuximab, evorpacept and dexamethasone in multiple myeloma (MM), sponsored by Sanofi. Primary endpoints: Determination of recommended dose of novel agents in combination with isatuximab and Very Good Partial Response (VGPR) rate or better. Planned start Oct 2024; status: authorised.
02
Drugs
isatuximabevorpaceptdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-514993-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514993-38-00.